To Our Shareholders
and Investors

• March 19, 2025

  Pharmaceuticals
  Launch of Uptravi® Tablets for Pediatric 0.05 mg for the Treatment of Pulmonary Arterial Hypertension in Japan
• March 05, 2025

  R & D
  CAP-1002: The U.S. FDA has accepted the Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy
• February 07, 2025

  Management & Finance
  Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2024
• January 30, 2025

  Corporate
  Termination of Litigation with Sarepta in Japan

Upcoming Events

• February 18, 2025
  R&D Meeting PDF1.7 MB
• February 07, 2025
  Conference Call(Q3/FY2024) PDF921 KB
• February 07, 2025
  FY2024 3rd Qtr results announcement PDF780 KB
• November 15, 2024
  IR Meeting(Q2/FY2024) PDF2.5 MB
• November 13, 2024
  FY2024 2nd Qtr results announcement PDF641 KB